2022
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
Yeong J, Lum H, Teo C, Tan B, Chan Y, Tay R, Choo J, Jeyasekharan A, Miow Q, Loo L, Yong W, Sundar R. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer 2022, 25: 741-750. PMID: 35661944, PMCID: PMC9226082, DOI: 10.1007/s10120-022-01301-0.Peer-Reviewed Original ResearchConceptsCombined positive scorePD-L1 combined positive scoreTumor proportion scorePD-L1Gastric cancerImmune cellsPD-L1 immunohistochemistry assaysProgrammed death-ligand 1Resection of gastric cancerStandard-of-care treatmentBackgroundImmune checkpoint inhibitorsGastric cancer immunotherapyPD-L1 positivityPD-L1 scoringPD-L1 immunohistochemistryDeath-ligand 1Metastatic gastric cancerPD-L1-positive samplesInter-assay concordanceCheckpoint inhibitorsDako 22C3ICI therapyCross-sectional studyCancer immunotherapyPatient selectionChoice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.
Tay R, Yeong J, Lum J, Teo C, Tan B, Chan Y, Choo J, Jeyasekhran A, Miow Q, Loo L, Yong W, Sundar R. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Journal Of Clinical Oncology 2022, 40: 4026-4026. DOI: 10.1200/jco.2022.40.16_suppl.4026.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune checkpoint inhibitor therapyPD-L1 CPSTumor proportion scorePD-L1Gastric cancerTissue microarrayImmune cellsPatients treated with ICI therapyPD-L1 expression statusPD-L1 immunohistochemistry assaysProgrammed death-ligand 1Resection of gastric cancerStandard-of-care treatmentGastric cancer immunotherapyPD-L1 scoringPD-L1 immunohistochemistryPD-L1 positivityDeath-ligand 1Metastatic gastric cancerPD-L1-positive samplesInter-assay concordanceNational University HospitalWhole slide analysisCut-off
2019
Epigenetic alternate promoter utilization and association with PD-L1 expression in Epstein–Barr virus positive gastric cancer.
Sundar R, Qamra A, Tan A, Zhang S, Ng C, Teh B, Lee J, Kim K, Tan P. Epigenetic alternate promoter utilization and association with PD-L1 expression in Epstein–Barr virus positive gastric cancer. Journal Of Clinical Oncology 2019, 37: e15509-e15509. DOI: 10.1200/jco.2019.37.15_suppl.e15509.Peer-Reviewed Original ResearchPD-L1 expressionPD-L1Gastric cancerEBV-negativeAnti-PD-1 immune checkpoint inhibitorsEBV-encoded RNA in situ hybridizationImmune-evasionProtein expression of PD-L1PD-L1 transcript expressionExpression of PD-L1Resistance to immune checkpoint inhibitionEpstein-Barr virus-positive gastric cancerEpstein-Barr virus-associated gastric cancerImmune checkpoint inhibitionImmune checkpoint inhibitorsPD-L1 immunohistochemistryPrimary tumor resectionPositive gastric cancerGastric cancer patientsEBV-negative samplesSamsung Medical CentreRNA in situ hybridizationCheckpoint inhibitorsCheckpoint inhibitionEBV status
2018
Transcriptional analysis of immune genes in Epstein–Barr virus-associated gastric cancer and association with clinical outcomes
Sundar R, Qamra A, Tan A, Zhang S, Ng C, Teh B, Lee J, Kim K, Tan P. Transcriptional analysis of immune genes in Epstein–Barr virus-associated gastric cancer and association with clinical outcomes. Gastric Cancer 2018, 21: 1064-1070. PMID: 29915957, DOI: 10.1007/s10120-018-0851-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedB7-H1 AntigenBiomarkers, TumorCD8 AntigensCohort StudiesDisease-Free SurvivalEpstein-Barr Virus InfectionsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHerpesvirus 4, HumanHumansImmunohistochemistryLymphocytes, Tumor-InfiltratingMaleMiddle AgedPerforinProgrammed Cell Death 1 ReceptorStomach NeoplasmsConceptsPD-L1PD-L1highPD-L1lowEBVaGC samplesImmune-related genesAssociated with worse disease-free survivalGastric cancerPD-L1 immunohistochemistry expressionPD-L1 transcript expressionExpression of PD-L1Levels of PD-L1Epstein-Barr virus-associated gastric cancerTumour-infiltrating lymphocyte patternPD-L1 expressionPD-L1 immunohistochemistryPrimary tumor resectionDisease-free survivalAssociated with higher expressionCases of EBVaGCGastric cancer patientsEBV-negative samplesSamsung Medical CentreAsian Cancer Research GroupImmune genesCancer Research Group